By preferentially degrading collagen type IV, in addition to collagen type I and III fibers, RLN2 overcomes the stromal barrier, enabling RLN2-secreting CAR-T cells to reach cancer cell nests and potentially enhance their cytolytic activity and antitumor efficacy. This evidence concerns the gene RLN2 and cancer.